Abstract
The seminal work by Shi et al. unveils a novel cytoprotective mechanism in intervertebral disc degeneration, whereby USP5-rich apoptotic extracellular vesicles (ApoEVs) stabilize the transcription factor E2F1 to suppress apoptosis and enhance DNA repair in nucleus pulposus cells. While this study elegantly reframes the reparative potential of ApoEVs, its conceptual and translational premises invite critical scrutiny. This letter highlights several overlooked challenges. We argue that the contextual duality of E2F1-a well-established regulator of both cell survival and senescence-poses a considerable therapeutic hazard, as sustained E2F1 stabilization may inadvertently trigger a senescent phenotype. Moreover, the generalizability of this mechanism remains uncertain: ApoEV cargo and functionality are highly dependent on the apoptotic stimulus, and vesicles derived from etoposide-induced apoptosis may not mirror those produced under pathophysiological disc conditions. Crucially, the proposed pathway-from vesicle internalization and endosomal escape of luminal USP5 to its nuclear trafficking and engagement with E2F1-represents a mechanistic black box requiring rigorous validation. Resolving these issues is essential to translating this compelling discovery into a safe and effective therapeutic strategy.